TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6608483

Group type: EXPERIMENTAL
Intervention: Vitamin D2 (50,000 IU p.o. two to three times weekly)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: 25-OH-D (20 to 50 mg p.o. daily as required)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control (no supplemental vitamin D treatment)
Number of subjects: 56
Study: 31549935

Group type: EXPERIMENTAL
Intervention: Robotic radical cystectomy
Number of subjects: 302

Group type: COMPARATOR
Intervention: Open radical cystectomy
Number of subjects: 302
Study: 29283597

Group type: EXPERIMENTAL
Intervention: 14-week, group-based parenting program (ADAPT)
Number of subjects: 336

Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 336
Study: 28139626

Group type: EXPERIMENTAL
Intervention: Cerebrolysin 20 ml per 200 ml of 0.9% NaCl solution, 1 time per day for 10 days (G1)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 200 ml 0.9% NaCl solution (G2)
Number of subjects: 40
Study: 24925592

Group type: EXPERIMENTAL
Intervention: Gestational diabetes
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Insulin-requiring gestational diabetes
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Glycaemic control in gestational diabetes
Number of subjects: 272
Study: 22154591

Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy plus adjuvant chemotherapy
Number of subjects: 508

Group type: COMPARATOR
Intervention: Concurrent chemoradiotherapy alone
Number of subjects: 508
Study: 21084077

Group type: EXPERIMENTAL
Intervention: HPV vaccine awareness and intention to become vaccinated
Number of subjects: 2295

Group type: EXPERIMENTAL
Intervention: Awareness of HPV vaccine by ethnicity
Number of subjects: 2295

Group type: EXPERIMENTAL
Intervention: Willingness to be vaccinated by ethnicity
Number of subjects: 2295

Group type: EXPERIMENTAL
Intervention: Education's effect on awareness and intention
Number of subjects: 2295

Group type: EXPERIMENTAL
Intervention: Awareness and desire for vaccination by language spoken at home
Number of subjects: 2295
Study: 18689368

Group type: EXPERIMENTAL
Intervention: Dextrose plus 2.4 g amino acids . kg(‐1) . d(‐1)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Dextrose (control group)
Number of subjects: 20
Study: 15714185

Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine/0.5 mg mL(‐1) sufentanil
Number of subjects: 20

Group type: COMPARATOR
Intervention: 0.2% ropivacaine alone
Number of subjects: 20
Study: 12798823

Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 2028

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2028
Study: 10226122

Group type: EXPERIMENTAL
Intervention: Immediate treatment with thermal balloon ablation (single intramuscular administration of GnRH analog)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Delayed treatment with thermal balloon ablation (without uterine preparation)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Immediate treatment
Number of subjects: 30

Group type: COMPARATOR
Intervention: Delayed treatment
Number of subjects: 30
Study: 8911942

Group type: EXPERIMENTAL
Intervention: Illusory change in size (brought about by presenting five converging lines in two different configurations under the disks)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (no illusory change in size)
Number of subjects: 8
Study: 1881743

Group type: EXPERIMENTAL
Intervention: Subcutaneous varicella vaccine
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Intramuscular varicella vaccine
Number of subjects: 166

Group type: COMPARATOR
Intervention: Both routes (subcutaneous and intramuscular)
Number of subjects: 166
Study: 6178592

Group type: EXPERIMENTAL
Intervention: Leukocyte IFN
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fibroblast IFN
Number of subjects: 0
Study: 30768060

Group type: EXPERIMENTAL
Intervention: RAMPO protocol
Number of subjects: 122

Group type: COMPARATOR
Intervention: Traditional protocols (Control)
Number of subjects: 122
Study: 28746164

Group type: EXPERIMENTAL
Intervention: Dapivirine intravaginal ring
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26037514

Group type: EXPERIMENTAL
Intervention: Premeal insulin injection before a high-carbohydrate meal
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: High-fructose meal
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control meal with premeal saline injection
Number of subjects: 10
Study: 24432671

Group type: EXPERIMENTAL
Intervention: Xiaoyan Zhitong Paste (XZP), applied externally, one to two pastes each time, exchanged once per 24 hours, for a total of two 7-day treatment courses.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo, applied externally in the same manner as XZP.
Number of subjects: 0
Study: 22208289

Group type: EXPERIMENTAL
Intervention: Multi-strategic practice change intervention implemented across all facilities to facilitate clinician risk assessment and provision of brief advice and referral.
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Telephone interviews with randomly selected clients who visited a community health facility in the last two weeks.
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Telephone interviews with randomly selected samples of clinicians from each facility group before and after the intervention.
Number of subjects: 56
Study: 19922896

Group type: EXPERIMENTAL
Intervention: Combined fixed-dose formulation of ticlopidine 250 mg/ginkgo extract 80 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Concomitant administration of ticlopidine 250 mg and ginkgo extract 80 mg
Number of subjects: 24
Study: 16990077

Group type: EXPERIMENTAL
Intervention: Donepezil (cholinesterase inhibitor)
Number of subjects: 769

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 769
Study: 15131408

Group type: EXPERIMENTAL
Intervention: Specialist genetics assessment
Number of subjects: 412

Group type: COMPARATOR
Intervention: Assessment by a breast surgeon (control)
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: Further counselling and testing within families
Number of subjects: 412
Study: 11600101

Group type: COMPARATOR
Intervention: Placebo phase
Number of subjects: 55

Group type: COMPARATOR
Intervention: Subgroup of patients hospitalized for less than 2 months after antipsychotic medications were restored
Number of subjects: 55
Study: 10423601

Group type: EXPERIMENTAL
Intervention: Moexipril 15 mg once daily
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Moexipril 30 mg once daily
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 25 mg once daily
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 50 mg once daily
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Moexipril 15 mg + Hydrochlorothiazide 25 mg
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Moexipril 30 mg + Hydrochlorothiazide 50 mg
Number of subjects: 272

Group type: COMPARATOR
Intervention: Moexipril monotherapy
Number of subjects: 272

Group type: COMPARATOR
Intervention: Diuretic or combination treatment
Number of subjects: 272
Study: 7943382

Group type: EXPERIMENTAL
Intervention: Cold pressor test (2 min)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Mental stress test (2 min of mental arithmetic)
Number of subjects: 9
Study: 3359909

Group type: EXPERIMENTAL
Intervention: Intraduodenal fat (Intralipid 10%)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Intravenous fat (Intralipid 10%)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Intraduodenal fat plus cholestyramine (20 g)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: All fat infusion groups (Intravenous and Intraduodenal)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Intravenous fat (group IV)
Number of subjects: 9
Study: 31698977

Group type: EXPERIMENTAL
Intervention: Cementless porous-coated hemispherical cups with electrochemically applied hydroxyapatite (BoneMaster) coating (PBM)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Cementless porous-coated hemispherical cups with porous coating alone (P)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: PBM cups
Number of subjects: 53

Group type: COMPARATOR
Intervention: P cups
Number of subjects: 53
Study: 31526690

Group type: EXPERIMENTAL
Intervention: Cognitive function Neuro‐QoL in pediatric patients with Sturge‐Weber syndrome
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Male gender
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Extent of skin involvement
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Total eyelid port-wine birthmark
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Eye involvement
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Total Sturge‐Weber syndrome involvement
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Younger age at seizure onset
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Antidepressant use
Number of subjects: 22
Study: 28215316

Group type: EXPERIMENTAL
Intervention: Aronia extract (500 mg daily)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 25199912

Group type: EXPERIMENTAL
Intervention: Low external resistance (40% of 1-repetition maximum)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: High external resistance (70% of 1-repetition maximum)
Number of subjects: 52
Study: 23811808

Group type: EXPERIMENTAL
Intervention: Acipimox
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Insulin
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 21523338

Group type: EXPERIMENTAL
Intervention: Nilotinib 300 mg BID
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Nilotinib 400 mg BID
Number of subjects: 79

Group type: COMPARATOR
Intervention: Imatinib 400 mg QD
Number of subjects: 79
Study: 17700649

Group type: COMPARATOR
Intervention: 3 meals/day (3M)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: 3 meals and 3 snacks/day (3+3M)
Number of subjects: 140
Study: 16514304

Group type: EXPERIMENTAL
Intervention: Behavioral intervention
Number of subjects: 4295
Study: 12899109

Group type: EXPERIMENTAL
Intervention: Indinavir with nucleoside-analogue reverse-transcriptase inhibitors (NRTI)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Indinavir with zidovudine and lamivudine
Number of subjects: 3

Group type: COMPARATOR
Intervention: NRTI monotherapy
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Indinavir
Number of subjects: 3
Study: 10872898

Group type: EXPERIMENTAL
Intervention: Vitamin E (400 IU/day)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both vitamins E and C
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Vitamin C (1 g/day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 9354709

Group type: EXPERIMENTAL
Intervention: Balloon angioplasty combined with stenting (ST)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Balloon angioplasty alone (BA)
Number of subjects: 51
Study: 8401167

Group type: EXPERIMENTAL
Intervention: Intervention by general practitioners (GP) for smoking cessation
Number of subjects: 450
Study: 3093045

Group type: EXPERIMENTAL
Intervention: Telephone reminder by the nurse
Number of subjects: 939

Group type: EXPERIMENTAL
Intervention: Personal reminder by the physician
Number of subjects: 939

Group type: EXPERIMENTAL
Intervention: Reminder by letter
Number of subjects: 939

Group type: COMPARATOR
Intervention: No reminder (Control group)
Number of subjects: 939

Group type: EXPERIMENTAL
Intervention: Patients contacted by nurse
Number of subjects: 939

Group type: EXPERIMENTAL
Intervention: Patients seen by physician
Number of subjects: 939
Study: 31937350

Group type: EXPERIMENTAL
Intervention: c-MeST (computerised memory specificity training)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 29939894

Group type: EXPERIMENTAL
Intervention: Periarticular analgesic injection (PAI)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo injection
Number of subjects: 40
Study: 26932345

Group type: EXPERIMENTAL
Intervention: Golimumab (GOL), administered subcutaneously, following a placebo control through weeks 16 and 24.
Number of subjects: 0
Study: 24576514

Group type: EXPERIMENTAL
Intervention: Routine manual aspiration thrombectomy with the Export catheter during PPCI
Number of subjects: 10700

Group type: COMPARATOR
Intervention: Percutaneous coronary intervention alone
Number of subjects: 10700
Study: 22691654

Group type: EXPERIMENTAL
Intervention: Oral nonsteroidal anti‐inflammatory drug (NSAID)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Oral gabapentin
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Intravenous (IV) 10% mannitol and steroid
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: IV 20% mannitol and steroid with oral gabapentin
Number of subjects: 59
Study: 20038515

Group type: EXPERIMENTAL
Intervention: FEC-D (anthracyclines plus docetaxel)
Number of subjects: 1996

Group type: COMPARATOR
Intervention: FEC100 (anthracyclines alone)
Number of subjects: 1996
Study: 18272891

Group type: EXPERIMENTAL
Intervention: Rituximab (1000 mg intravenous on days 1 and 15)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study: 16204792

Group type: EXPERIMENTAL
Intervention: Intranasal histamine (4 mg/ml, 0.1 ml)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Intranasal saline
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Intranasal histamine
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Nasal intensified breathing
Number of subjects: 14
Study: 14576754

Group type: EXPERIMENTAL
Intervention: 200 mug folic acid/day
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: 40 mg pyridoxine/day
Number of subjects: 121

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 121
Study: 10665894

Group type: EXPERIMENTAL
Intervention: Melatonin (2 mg controlled-release formulation)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 8717596

Group type: EXPERIMENTAL
Intervention: TMP-SMX (160/800 mg) daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aerosolized pentamidine (300 mg) monthly
Number of subjects: 0

Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 0
Study: 8390084

Group type: EXPERIMENTAL
Intervention: calcitonin
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: calcitonin+fluoride
Number of subjects: 50

Group type: COMPARATOR
Intervention: calcium+vitamin D supplements
Number of subjects: 50
Study: 3443597

Group type: EXPERIMENTAL
Intervention: Pranayamic breathing exercises using a Pink City lung exerciser alone
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Exercises using the lung exerciser with hot, humid air
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (placebo administration)
Number of subjects: 12
Study: 31674093

Group type: EXPERIMENTAL
Intervention: Bioengineered bilayered living cell construct (BLCC) plus compression therapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Compression therapy (control)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Bioengineered bilayered living cell construct (BLCC)
Number of subjects: 30
Study: 28574780

Group type: EXPERIMENTAL
Intervention: Various interventions targeting treatment engagement in youth mental health services
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Specific practices distilled from effective interventions
Number of subjects: 50
Study: 27192358

Group type: EXPERIMENTAL
Intervention: Increased sanitation coverage (27 percentage points)
Number of subjects: 301

Group type: COMPARATOR
Intervention: Community drinking water sources with detected pathogens
Number of subjects: 301

Group type: COMPARATOR
Intervention: Higher levels of human and animal fecal marker detection in homes
Number of subjects: 301

Group type: COMPARATOR
Intervention: Tubewells
Number of subjects: 301

Group type: COMPARATOR
Intervention: Ponds
Number of subjects: 301
Study: 26215589

Group type: EXPERIMENTAL
Intervention: Extensive program with motivational interviewing (MI) sessions by trained occupational physicians, 4 face-to-face and 3 by telephone, and more choices of health promotion activities in the HRA.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Limited health program (control) consisting of an HRA as a decision aid for lifestyle changes and a newsletter every 3 months.
Number of subjects: 0
Study: 23306144

Group type: EXPERIMENTAL
Intervention: Incredible Years (IY) parenting program
Number of subjects: 481

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 481
Study: 20613471

Group type: EXPERIMENTAL
Intervention: Group 0 (radiofrequency denervation based solely on clinical findings)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Group 1 (denervation contingent on a positive response to a single diagnostic block)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Group 2 (denervation only if positive response to comparative blocks with lidocaine and bupivacaine)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Group 0
Number of subjects: 151

Group type: COMPARATOR
Intervention: Group 1
Number of subjects: 151

Group type: COMPARATOR
Intervention: Group 2
Number of subjects: 151
Study: 18568441

Group type: EXPERIMENTAL
Intervention: Femal (160 mg twice-daily for four menstrual cycles)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 16616126

Group type: EXPERIMENTAL
Intervention: Complete group (360 degrees of axial walls)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Palatal group (180 degrees of axial walls)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Labial group (180 degrees of axial walls)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Proximal group (180 degrees of axial walls)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Level group (no retained coronal tooth structure)
Number of subjects: 50
Study: 12789181

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) with Metvix and 75 J/cm² red light, performed twice weekly for 12 weeks, then once weekly.
Number of subjects: 10

Group type: COMPARATOR
Intervention: Paromomycin sulfate, administered once daily.
Number of subjects: 10
Study: 10619534

Group type: EXPERIMENTAL
Intervention: Dietary intervention with counseling to adopt a diet containing 28% or less of calories from total fat, <8% saturated fat, up to 9% polyunsaturated fat, and 11% monounsaturated fat, and dietary cholesterol intake of less than 75 mg/1,000 kcal
Number of subjects: 663

Group type: COMPARATOR
Intervention: Usual-care group (control)
Number of subjects: 663
Study: 7646090

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (20 ppm x 10 minutes)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Intravenous prostacyclin (20 ng.kg‐1.min‐1 x 10 minutes)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide
Number of subjects: 13

Group type: COMPARATOR
Intervention: Intravenous prostacyclin
Number of subjects: 13
Study: 2520394

Group type: EXPERIMENTAL
Intervention: Codetron (Group A)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham Codetron (Group B)
Number of subjects: 0
Study: 616209

Group type: EXPERIMENTAL
Intervention: Jodamid
Number of subjects: 215

Group type: COMPARATOR
Intervention: Metrizoic acid
Number of subjects: 215
Study: 31183585

Group type: EXPERIMENTAL
Intervention: Individual counseling (1-3 sessions) and group counseling (6 sessions per week for 6 weeks)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 80
Study: 28377389

Group type: EXPERIMENTAL
Intervention: Prolonged-release tacrolimus suspension administered orally
Number of subjects: 20

Group type: COMPARATOR
Intervention: Prolonged-release tacrolimus suspension administered via nasogastric tube
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intact capsules
Number of subjects: 20
Study: 25205761

Group type: EXPERIMENTAL
Intervention: Off-the-shelf, extra-depth footwear
Number of subjects: 120
Study: 23955148

Group type: EXPERIMENTAL
Intervention: NVS123 formulated as dry filled capsules administered orally with high-fat meal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alternative formulations developed and assessed in preclinical and/or clinical studies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amorphous formulation of NVS123
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gastroplus population simulations
Number of subjects: 0
Study: 21563916

Group type: EXPERIMENTAL
Intervention: Radioiodine therapy (131I) with an administered activity of 1.85-4.07 MBq per gram of thyroid tissue (average 261 ± 162 MBq) in Group 3
Number of subjects: 600

Group type: COMPARATOR
Intervention: Radioiodine therapy (131I) with varying activities in other groups
Number of subjects: 600
Study: 19686420

Group type: EXPERIMENTAL
Intervention: Terlipressin (1 mg intravenous)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 16303780

Group type: EXPERIMENTAL
Intervention: HFR (Haemodiafiltration with online regeneration of ultrafiltrate)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Online HDF (Haemodiafiltration)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Wash-out period with HD (standard bicarbonate dialysis)
Number of subjects: 25
Study: 15504192

Group type: EXPERIMENTAL
Intervention: Rocuronium 0.4 mg kg(‐1)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Succinylcholine 1 mg kg(‐1)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Control (no relaxant)
Number of subjects: 161
Study: 10795733

Group type: EXPERIMENTAL
Intervention: Equation development sample (n = 50)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Equation validation sample (n = 25)
Number of subjects: 75
Study: 9061310

Group type: EXPERIMENTAL
Intervention: Unheated cornstarch (106 g of CHO)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Mixed equicaloric meal (58 g of CHO)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Smaller mixed meal (17 g of CHO)
Number of subjects: 10
Study: 7930243

Group type: EXPERIMENTAL
Intervention: Radiofrequency balloon angioplasty
Number of subjects: 31

Group type: COMPARATOR
Intervention: Other procedures as rescue
Number of subjects: 31
Study: 2467137

Group type: EXPERIMENTAL
Intervention: Amlodipine 10 mg once daily added to captopril 25 mg twice daily for 4 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo added to captopril 25 mg twice daily for 4 weeks
Number of subjects: 0
Study: 29775170

Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate 150 mg twice daily
Number of subjects: 120

Group type: COMPARATOR
Intervention: Dose-adjusted warfarin (INR 2-3)
Number of subjects: 120
Study: 28148474

Group type: EXPERIMENTAL
Intervention: BPMED intervention (text messaging support)
Number of subjects: 123